Thomas Jackson

I have been a postdoctoral researcher in Prof Paresh Vyas’ research group at the MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine since 11/2016.  My position is funded by OxStem Oncology a subsidiary company of OxStem (http://www.oxstem.co.uk/), whose vision is to develop in situ cell programming therapies. OxStem oncology aims to identify new classes of drug that with differentiate ‘cancer stem-like cells’ to more benign states that will improve clinical outcomes and overcome resistance/relapse. To this end I have developed FACS bases screens to identify compounds that differentiate appropriate AML cell line models. My research is now focused on further characterising compounds that have been identified by initial screening as well as developing higher throughput screening methods.

Previously, I obtained my PhD form the University of Southampton under the supervision of Prof Mark Cragg and Paul Townsend. Thesis title: The role of stem cell transcription factors in the response of tumour cells to DNA damage. As a postdoctoral researcher at the University of Manchester I continued this work with Prof Paul Townsend, as well as I working on a diverse range of new projects from cancer biomarker discovery to cell death and survival mechanisms in osteoarthritis.